Sodium oligomannate is an oral sugar-chain drug from brown seaweed for mild to moderate Alzheimer's disease. One company-run trial found a better memory-and-thinking score without a clear gain in daily independence, behavior, or clinician's rating; an earlier trial missed its main thinking result. Harm looked limited; high blood lipids were more common. No human test exists without dementia. China's approval was not renewed in 2025 and production was reported stopped. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting LDL-C and triglycerides | LDL-C under 100 mg/dL (under 70 mg/dL if artery disease is present); triglycerides under 100 mg/dL | High blood lipids were more common on drug than on placebo |
| eGFR | Over 90 mL/min/1.73 m², or stable versus the person's own baseline if no oligomannate-specific target is set | The absorbed fraction is cleared by the kidney in animal studies |
| ALT | Under 25 U/L, or stable versus baseline where no drug-specific target exists | The approval safety summary listed higher readings on drug than on placebo |
| Cognitive score (MMSE or ADAS-Cog) | No fixed blood-style optimum; change from the person's baseline on the same test is followed | This is the outcome that moved in the phase 3 trial |
Cadence: Before a first dose: cognitive score, fasting lipids, kidney filtration, and liver enzymes. Cognitive score and lipids again at about 4 weeks, then every 3–6 months; kidney and liver tests on that same cadence unless a result is abnormal.